Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic γδ T cells
- Development stage
- Unknown
- Lead developer
- Chinese PLA General Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic γδ T cells (Chinese PLA General Hospital) is an adoptive cellular immunotherapy consisting of gamma delta (γδ) T cells derived from healthy donors. Unlike conventional αβ T cells, γδ T cells recognize antigens in a non-MHC-restricted manner, typically responding to phosphoantigens and stress-induced ligands (such as MICA/B) frequently expressed on malignant cells. This allows for "off-the-shelf" use without the high risk of graft-versus-host disease (GvHD). The therapy is being evaluated by the Chinese PLA General Hospital for the treatment of various malignant solid tumors and B-cell non-Hodgkin lymphoma, either as a monotherapy or in combination with standard treatments, to leverage the cells' natural cytotoxicity and cytokine-secreting capabilities.
- Other names
- allogeneic gamma delta T cellsallogeneic γδ T-cell therapy
02
Targets
NKG2D (Natural killer group 2 member D receptor)BTN3A1 (Butyrophilin subfamily 3 member A1)MICB (Major histocompatibility complex class i-related protein B)MICA (Major histocompatibility complex class I-related protein A)
Beyond the preview
Go deeper on allogeneic γδ T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic γδ T cells.